Markets:

Overview

News

Currencies

International

Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

24.90 -0.07 (-0.28%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Edgewise Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Edgewise Therapeutics Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

October 13, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 27th International Hybrid Annual Congress of the World Muscle Society

October 06, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 16, 2022

From Edgewise Therapeutics, Inc.

Via Business Wire

Recap: Edgewise Therapeutics Q2 Earnings ↗

August 04, 2022

Edgewise Therapeutics (NASDAQ:EWTX) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

RBC Capital Says This Dystrophy Stock 'Is Worth A Look' ↗

June 22, 2022

Via Benzinga

Edgewise's Dystrophy Candidate Lowers Muscle Damage Biomarkers ↗

June 21, 2022

Via Benzinga

Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday ↗

September 16, 2022

Gainers

Via Benzinga

Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

September 13, 2022

From Edgewise Therapeutics

Via Business Wire

Recap: Edgewise Therapeutics Q1 Earnings ↗

May 11, 2022

Edgewise Therapeutics (NASDAQ:EWTX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

March 25, 2022

On Friday, 166 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...

Via Benzinga

Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday ↗

September 14, 2022

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...

Via Benzinga

Edgewise Therapeutics Announces Proposed Offering of Common Stock

September 13, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

September 11, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)

September 07, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Reports Second Quarter 2022 Financial Results

August 04, 2022

From Edgewise Therapeutics, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022 ↗

August 25, 2022

Upgrades

Via Benzinga

Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9

August 03, 2022

From Edgewise Therapeutics

Via Business Wire

6 Blue-Chip Stocks to Sell Now ↗

July 18, 2022

This article is about 6 blue-chip stocks to sell now. They are severely overvalued or are likely to move down soon with a recession.

Via InvestorPlace

Edgewise Therapeutics Initiates Mid-Stage Muscular Dystrophies Study ↗

July 12, 2022

Edgewise Therapeutics (NASDAQ: EWTX) announced the initiation of the CANYON Phase 2 clinical trial evaluating EDG-5506 in individuals with Becker Muscular Dystrophy (BMD).

Via Benzinga

Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)

July 12, 2022

From Edgewise Therapeutics

Via Business Wire

The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial ↗

June 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

June 20, 2022

From Edgewise Therapeutics

Via Business Wire

New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference

June 16, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at Upcoming Investor Conferences

May 31, 2022

From Edgewise Therapeutics

Via Business Wire

Analyst Ratings for Edgewise Therapeutics ↗

May 12, 2022

Over the past 3 months, 4 analysts have published their opinion on Edgewise Therapeutics (NASDAQ:EWTX) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Edgewise Therapeutics Reports First Quarter 2022 Financial Results

May 11, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at Upcoming Investor Conferences

May 03, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise-Funded Natural History Trial of Becker Muscular Dystrophy (BMD) Now Enrolling

April 14, 2022

From Edgewise Therapeutics

Via Business Wire

Stocks That Hit 52-Week Lows On Thursday ↗

March 24, 2022

On Thursday, 112 stocks made new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: Stanley Black & Decker (NYSE:SWK) was the largest firm by market...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

March 23, 2022

On Wednesday, 63 companies set new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.